Serving Kansas City, Missouri & Surrounding Areas
Midtown Recovery Center

Addiction

What Is SR-17018? Risks, Dependence, and How to Quit

experimental research chemical

You may have seen SR-17018 pitched online as a safer opioid. It’s an experimental compound, sold as a research chemical, with no approved use and no completed human trials. Even so, people are buying it to manage opioid withdrawal.

That raises real questions: How does it work, and what do we actually know about tolerance, overdose risk, and withdrawal? Here’s what the research says, and where you can find safe, proven support.

What Is SR-17018?

SR-17018 is an experimental compound that came out of a research lab. Dr. Laura Bohn’s team discovered it. The goal was a pain reliever with fewer of the dangerous side effects that come with morphine.

To do that, researchers built it to act on the mu-opioid receptor, the same target that opioid pain medicines use. Chemists place it in a class called benzimidazolones, nicknamed “orphines.”

Its chemical name is 5,6-dichloro desmethylchlorphine. Chemists also record its structure in SMILES notation, a text code that describes a molecule’s shape.

Early lab results looked promising. But here’s the catch: SR-17018 isn’t an approved medication. It has no approved formulation, no standard dose, and no completed human trials.

Despite that, vendors sell it online as a research chemical. Because it acts on the μ-opioid receptor, it continues to be part of the conversation about synthetic opioids. That group also includes fentanyl, and synthetic opioids cause most opioid overdose deaths in the U.S.

Why do you need to know this? Because nobody can verify what a gray-market product actually contains. Their strength and purity are unknown. Researchers still study SR-17018 as a template for safer pain relief, but no controlled human trials exist yet.

How SR-17018 Works in the Brain

When an opioid binds the mu-opioid receptor, it sets off two signals inside the cell. G protein signaling helps drive pain relief. The second signal, beta-arrestin, has been linked to side effects such as tolerance, constipation, and slowed breathing.

So researchers had an idea: What if a drug could switch on the first signal and mostly skip the second? That approach is called biased agonism. Early tests suggested SR-17018 fit the bill.

Here’s what makes it unusual:

In lab tests, SR-17018 keeps MOR signaling going for a long time. In a GTPγS binding assay, the receptor stayed active even after researchers washed the drug away.

USF Health researchers say it binds the receptor differently from morphine, oxycodone, and fentanyl. According to those researchers, that leaves the receptor open to the body’s own natural pain relievers.

Later studies found that after about 30 minutes, SR-17018 triggers receptor changes that match those of a full agonist. Those changes lasted for hours, so some scientists now question the “biased” label.

Additionally, a separate study found low intrinsic efficacy and no clear bias, a profile closer to buprenorphine. Early tests used short exposure times, which may have missed these effects. As such, researchers still can’t say how it will behave in people.

What Research Shows About Pain Relief

The big question is: does SR-17018 relieve pain? In animals, it does. Researchers tested it in mouse models of pain. Early results looked strong. Scientists use three common tests because they give a quick, repeatable read on pain relief. Here’s how SR-17018 fared:

  • Hot plate test: Mice stand on a heated surface, and researchers time their reaction. SR-17018 kept working with no sign of tolerance.
  • Tail immersion test: A mouse’s tail goes into heated water. Here, tolerance builds up at a rate similar to morphine and oxycodone.
  • Formalin test: This one models longer-lasting pain. SR-17018 kept its pain relief. Oxycodone lost strength.

Note: Tolerance may depend on the type of pain and how researchers measure it. In other words, the same compound can look rather different from one test to the next.

Early work in mice also suggested a wide gap between pain-relieving doses and doses that slowed breathing. But a later study found those two effects follow a similar timeline.

That said, no controlled human trials exist, so SR-17018 has no proven role in pain management. Despite the early promise, you can’t treat these findings as irrefutable proof.

The Risks of SR-17018

SR-17018 was meant to be safer than its peers. But that hasn’t been proven in people, and several risks remain. Here’s what the research and regulators have flagged:

  • Tolerance: Tolerance didn’t appear in the hot plate test, but it did in the tail immersion test. Some people also use SR-17018 to “reset” their tolerance. The DEA warns that this can raise the risk of a fatal overdose on the next dose of another drug.
  • Physical dependence: Federal regulators cite animal data showing SR-17018 can produce it. In other words, your body can adapt to it, and stopping may bring withdrawal.
  • Respiratory depression: Early studies hinted at less respiratory depression. Later work found similar timing for pain relief and breathing suppression. No one has shown it’s safer for breathing in people.
  • Fatal overdose: Strength and purity vary from product to product. Because of that, no one can say what a safe dose looks like. Orphines have also turned up alongside other drugs, including fentanyl, and routine drug screens may miss them.
  • Unknown long-term effects: Since no controlled human trials exist, nobody knows what regular use does over time.

Still, many people turn to SR-17018 hoping to ease opioid withdrawal. While that hope is understandable, an untested compound can leave you in a riskier spot than before.

SR-17018: Risk of Overdose

Naloxone may help in a suspected opioid overdose, and lab work shows SR-17018’s receptor effects respond to it. Even so, nobody knows how well it works for an SR-17018 overdose in people.

Fortunately, naloxone is widely available and easy to use. If you suspect an overdose, call 911 and administer naloxone right away. Stay with the person until help arrives.

No, not anymore.

On August 27, 2026, the DEA placed SR-17018 in Schedule I of the Controlled Substances Act. The temporary order runs until August 27, 2028.

Note: Schedule I covers drugs the DEA says have a high potential for abuse and no accepted medical use. Retail sales aren’t allowed, and unauthorized possession can lead to prosecution.

So even when a vendor labels it a research chemical, that label doesn’t change the rules. The DEA can also extend the order by one year or make it permanent.

SR-17018 Withdrawal

Many people try SR-17018 after several attempts to quit opioids. That’s common, and it’s nothing to be ashamed of. But can SR-17018 actually ease opioid withdrawal? Some people say it can. Here’s what the evidence tells us so far:

  • Mouse studies: SR-17018 reversed morphine tolerance and prevented morphine withdrawal in mice. That’s why the idea caught on.
  • A small registry: 30 people reported their own experiences, and 80% noted some improvement. But there was no control group.
  • Dependence: Federal regulators cite animal data showing physical dependence can develop. So stopping SR-17018 itself may bring withdrawal symptoms.

Reminder: Since none of this has been tested in controlled human trials, SR-17018 isn’t a proven treatment.

Either way, opioid withdrawal is hard on its own. Common withdrawal symptoms include muscle aches, nausea, sweating, anxiety, and trouble sleeping. Morphine withdrawal follows a similar pattern.

Here’s another reason not to go at it alone: Tolerance drops during withdrawal. So returning to your usual dose can cause a fatal overdose.

Fortunately, you don’t have to white-knuckle it. Medical support can ease the process and keep you safe. A care team monitors your symptoms and helps you plan what comes next.

Treatment Options for Opioid Use Disorder

Opioid use disorder is treatable. With the right support, recovery is within your reach.

Medication-Assisted Treatment

Medication-assisted treatment combines medicine with counseling. Medicines, such as buprenorphine and methadone, can reduce cravings and ease withdrawal symptoms in people with opioid use disorder.

Our MAT options include Suboxone, Sublocade, and Vivitrol. Our MAT options include Suboxone, Sublocade, and Vivitrol.

Levels of Care

Our structured programs include:

  • Partial Hospitalization (PHP): Monday to Saturday, 9:00 am to 2:45 pm, typically from 4 to 6 weeks.
  • Intensive Outpatient (IOP): A day track (9:00 am to 12:00 pm) or an evening track (5:30 pm to 8:30 pm), typically from 30 to 90 days.

Additionally, family sessions are part of the program and can be held up to once a week. More importantly, our therapists are credentialed in CBT, DBT, and EMDR. If you need medical detox first, we can refer you to a detox provider.

How and Where to Get Started

Start with us. Admissions is available 24/7. Same-day admission may be available once we can verify your insurance and finish your initial assessment. We also work with all major commercial insurance companies. Help is only a call away.

Final Thoughts

If you’re using SR-17018 or thinking about trying it, talk to someone first. Our team can answer your questions, explain your options, and help you take the next step.

Many of our team members are in recovery themselves or have seen addiction up close in their own families. That means you’ll talk with people who understand your position.

So, call Midtown Recovery Center today. A single call can start your path to safe, proven care.

Related articles

Kratom Addiction Treatment

Treatment

Kratom Detox: How to Get Off Kratom Safely

Kratom dependence is real, and withdrawal can look a lot like opioid withdrawal. A step-by-step look at getting off it safely, what support is available, and when to ask for medical help instead of going it alone.

Read article

Start Your Recovery Today — Same Day Admissions Available

24/7 Admissions Support

Verify Your Insurance

Submit your information and our admissions team will verify your benefits within hours. It's free, confidential, and there's no obligation to enroll.

Confidential. No obligation to enroll.

Prefer to talk it through? Call (816) 640-8967